Patient Power®
Get Email Alerts!
Health Topics
Multiple Myeloma Health Center
Health Center Home Audio Programs Videos Conference Coverage
  • ASH 2011
    • Live Events
  • SCCA Myeloma Town Hall 2011
    • Search by Keyword:
    Search by Health Topic:
    View all Health Topics >
    Spring Survey 2012 Results

    The Latest Myeloma News from the American Society of Hematology Meeting

    PROGRAM DETAILS:

    Patient Power founder and host, Andrew Schorr, attended the 2007 American Society of Hematology annual meeting in Atlanta, Georgia, where more than 21,000 scientists and physicians came together to discuss and learn about new treatments and clinical trial results for patients with multiple myeloma. In this program, Andrew interviewed three of the leading experts in Multiple Myeloma: Dr. Brian Durie, Dr. James Berenson and Dr. Sagar Lonial. They each shared why they are excited about the news presented at the meeting and what the data means for patients.

    On this episode, each expert brings their point-of-view on topics ranging from the latest information in clinical trials to combination therapies to the role of transplant and dietary supplementation in an aging population. Dr. Brian Durie, from the Cedars-Sinai Comprehensive Cancer Center in Los Angeles and medical director for the International Myeloma Foundation discusses the exciting news about combining novel agents Velcade, Revlimid, and thalidomide and the progress seen in frontline treatment with Revlimid and Dexamethasone combinations. Dr. Berenson, founder, president, and chief executive officer of the Institute for Myeloma and Bone Cancer Research, brings his perspectives on using Velcade with chemotherapeutic agents as well as his thoughts on maintaining a good quality of life for multiple myeloma patients. Dr. Sagar Lonial, from the Winship Comprehensive Cancer Center at Emory University, shares his thoughts on transplant and helps define the meaning of “CR” or Complete Remission and “VGPR” or Very Good Partial Remission.

    As always, Andrew asked the questions that patients need answered so they can be their own best advocates and get the very best treatment available for their disease. In this program, the expert guests define how they approach determining the appropriate treatment for individual patients and outline all the various options offered so you can have a meaningful conversation with your doctor as you work out your course of therapy.

    Get Email Updates:

    Get updated automatically when new content about Multiple Myeloma has been posted.
    Privacy Policy
    Multiple Myeloma
    EXPERTS & GUESTS:
    Brian G.M. Durie, M.D.
    Myeloma Specialist, Cedars-Sinai Medical Center
    Brian G.M. Durie, MD is the Chairman of the Board of the International Myeloma Foundation and a myeloma specialist at Cedars-Sinai Comprehensive Cancer Center in Los Angeles. He is also a member of the IMF Scientific Advisory Board. Dr. Durie co-created the Durie/Salmon Myeloma Staging System, has written over 300 research papers, five books, twelve book chapters. Dr. Durie is... more >

    James Berenson, M.D. James Berenson, M.D.
    Founder, President and Medical and Scientific Director, Institute for Myeloma and Bone Cancer Research
    James Berenson, M.D. is the Founder, President & Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. Dr. Berenson has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 25 years. He has been involved in many of the major breakthroughs that have brought new treatments for... more >

    Sagar Lonial, M.D. Sagar Lonial, M.D.
    Associate Professor, Emory Healthcare
    Dr. Sagar Lonial is an Associate Professor at the Winship Cancer Institute of Emory University, and is also Director of Translational Research, B-cell malignancy program. He is on staff and works both on the bone marrow transplant service as well as in the B-cell malignancy clinic. Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that received... more >

    TRANSCRIPT:

    1. Introduction LISTEN
    2. Positive News from ASH for Patients with Multiple Myeloma LISTEN
    3. Dr. Lonial's Comments on Transplant Therapy LISTEN
    4. Defining PR, CR, and VGPR LISTEN
    5. Pros and Cons of the Various Combination Drug Therapies LISTEN
    6. Does Age Play a Role in Deciding Treatment Options? LISTEN
    7. The Complexities of Determining Treatment Options for Patients LISTEN
    8. Treatment Considerations for Older Patients LISTEN
    9. Determining a Treatment Course for the Newly Diagnosed LISTEN
    10. Are There Dietary Supplements for Fighting Multiple Myeloma and Helping with Side Effects? LISTEN
    11. The Differences Between "Smoldering" Myeloma and High-Risk Disease LISTEN
    12. The Role of Transplant in Older Age Groups LISTEN
    13. In Summary: The Outlook is Positive LISTEN

    RELATED LINKS: